Immuneering Corporation — Income Charts
15 quarters of history · ending 2023-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↓-100.0% -$455
$0
Cost of Revenue
$0
Gross Profit↓-100.0% -$455
$0
R&D↑+20.6% +$2M
$12M
D&A↑+16.8% +$13K
$90K
Operating Income↓-5.6% -$738K
$-14M
EBITDA↑+16.8% +$13K
$90K
Interest Income↑+46.1% +$238K
$754K
Net Income↑+1.9% +$249K
$-13M
Gross Margin
100.0%
Operating Margin↓-32590.0pts
-34362.0%
Net Margin↓-31696.1pts
-33466.2%
ETR (Continuing Operations)↑+0.0pts
0.0%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-9.3pts
-3.2%
Operating Lease Cost↓-10.7% -$24K
$201K
Revenue YoY Variation↓-0.2pts
-100.0%
Income YoY Variation↑+48.8pts
-5.6%
Revenue QoQ Variation↓-96.9pts
-100.0%
Income QoQ Variation↑+10.1pts
-3.1%